NCT07000409 The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.
| NCT ID | NCT07000409 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Postherpetic Neuralgia |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-05-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the effectiveness of ultra-Sound guided Erector spinae block (ESB) with Betamethasone as an adjuvant to standard medical protocol in the management of truncal chronic post herpetic neuralgia.
Eligibility Criteria
Inclusion Criteria: * Patients age between 18 and 75. * Patients with American Society of Anesthesiologists (ASA) II and III status. * Patients diagnosed with truncal chronic post herpetic neuralgia( neuropathic pain persistent for more than 3 months from the onset of rash appearance ) Exclusion Criteria: * Patients unable to comprehend the informed consent. * Patients on long term opioid regimens. * Patients with impairment in hepatic (Alanine aminotransferase (ALT) \>50 U/L, and/or Aspartate aminotransferase (AST): \>45 U/L) or renal functions( creatinine level ≥1.5 mg/dL) * Patients on anti-coagulation regimens. * Patients with coagulation abnormalities (i.e. international normalized ratio (INR) ≥1.5 and/or platelets ≤50000) * Local infection in the site of the block. * Patients with body mass index (BMI) \> 35.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07000409 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Postherpetic Neuralgia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07000409 currently recruiting?
Yes, NCT07000409 is actively recruiting participants. Contact the research team at nadarefaat1994@gmail.com for enrollment information.
Where is the NCT07000409 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07000409 clinical trial?
NCT07000409 is sponsored by Cairo University. The trial plans to enroll 40 participants.